Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Coates

Showing results (291-300 of 343) with videos related to

Pageof 35
Sort By:
Rheumatology (Oxford, England)|May 31, 2022
The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDsLaura Tucker, Alexander Allen, David Chandler, et al.
Rheumatology and Therapy|June 8, 2020
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension StudyPeter Nash, Laura C Coates, Alan J Kivitz, et al.
Seminars in Arthritis and Rheumatism|February 18, 2021
Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiativeAnna Antony, Richard Holland, Maria-Antonietta D'Agostino, et al.
The Journal of Rheumatology|July 7, 2023
Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working GroupYing-Ying Leung, William Tillett, Maarten de Wit, et al.
Rheumatology (Oxford, England)|October 24, 2020
Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scopeWilliam Tillett, Alexander Allen, Laura Tucker, et al.
The Journal of Rheumatology|February 12, 2010
Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008Laura C Coates, Dennis M McGonagle, Richard Hodgson, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 UpdatesYing Ying Leung, William Tillett, Ana-Maria Orbai, et al.
Annals of the Rheumatic Diseases|February 14, 2012
Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohortJohn Bowes, Pauline Ho, Edward Flynn, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 22, 2024
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic ArthritisStefan Siebert, Laura C Coates, Georg Schett, et al.
The Lancet. Rheumatology|January 26, 2024
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL BalancePeter Nash, Philip J Mease, Dona Fleishaker, et al.
Pageof 35

Showing results (291-300 of 343) with videos related to

Sort By:
Pageof 35
Rheumatology (Oxford, England)|May 31, 2022
The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDsLaura Tucker, Alexander Allen, David Chandler, et al.
Rheumatology and Therapy|June 8, 2020
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension StudyPeter Nash, Laura C Coates, Alan J Kivitz, et al.
Seminars in Arthritis and Rheumatism|February 18, 2021
Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiativeAnna Antony, Richard Holland, Maria-Antonietta D'Agostino, et al.
The Journal of Rheumatology|July 7, 2023
Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working GroupYing-Ying Leung, William Tillett, Maarten de Wit, et al.
Rheumatology (Oxford, England)|October 24, 2020
Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scopeWilliam Tillett, Alexander Allen, Laura Tucker, et al.
The Journal of Rheumatology|February 12, 2010
Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008Laura C Coates, Dennis M McGonagle, Richard Hodgson, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 UpdatesYing Ying Leung, William Tillett, Ana-Maria Orbai, et al.
Annals of the Rheumatic Diseases|February 14, 2012
Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohortJohn Bowes, Pauline Ho, Edward Flynn, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 22, 2024
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic ArthritisStefan Siebert, Laura C Coates, Georg Schett, et al.
The Lancet. Rheumatology|January 26, 2024
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL BalancePeter Nash, Philip J Mease, Dona Fleishaker, et al.
Pageof 35